Brain Connectivity Imaging Markers To Confirm Diagnosis For Bipolar Vs. Unipolar Depression – A Connectome Approach.
Funder
National Health and Medical Research Council
Funding Amount
$434,369.00
Summary
Differentiating Bipolar disorders from Unipolar Depression is a major clinical challenge. This misdiagnosis hinders optimal clinical care and has many deleterious consequences such self-harm, increased chances of suicide, poor prognosis, and greater health care costs related to this disorder. This project will provide urgently-needed advance in accurate identification of Bipolar disorders using Magnetic Resonance Imaging and remove one of the key obstacles to accurate diagnosis.
Depressive And Bipolar Disorders: Causes, Presentation And Treatment Innovations
Funder
National Health and Medical Research Council
Funding Amount
$7,100,605.00
Summary
Depression and bipolar disorder are two of Australia’s leading causes of disease burden, with 3-4 million Australians affected during their lifetime. However, despite being such a serious health burden, there are major shortcomings to current understanding and management. This research program aims to further our knowledge of the causes and presentations of the mood disorders, and to improve and “tailor” treatment for the many Australians who suffer from these highly disabling illnesses.
It is widely accepted that just under half of all people with bipolar disorder have a chronic physical illness. The one neglected comorbidity is osteoporosis. In this project, the association between bipolar disorder and bone fragility will be examined. Additionally, a potential common mechanism, systemic inflammation, which may underlie both diseases, will be investigated as a potential mediator of the relationship.
Interactions Between The Serotonin Transporter And Sympathetic Nervous Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart
Funder
National Health and Medical Research Council
Funding Amount
$527,109.00
Summary
There is evidence that patients with major depressive disorder (MDD) are at increased risk of developing heart disease. While the mechanisms responsible remain unknown we have previously demonstrated that cardiac sympathetic nervous activity in patients with MDD follows a bimodal distribution, with values in some patients being extraordinarily high. In this project we will determine the physiological consequences of sympathetic activation in patients with MDD.
Novel Therapies, Risk Pathways And Prevention Of Mood Disorders
Funder
National Health and Medical Research Council
Funding Amount
$863,413.00
Summary
Concordant with the NHMRC priorities, this fellowship will principally focus on the development of novel therapies for mood disorders. We have pilot data that the amino acid, N acetyl cysteine reduces symptoms in unipolar and bipolar disorder and schizophrenia. We will further delineate the spectrum of efficacy, mechanisms of action and tolerability profile of this and related agents. We also will study risk factors and pathways for the development of depression, to develop public health strateg ....Concordant with the NHMRC priorities, this fellowship will principally focus on the development of novel therapies for mood disorders. We have pilot data that the amino acid, N acetyl cysteine reduces symptoms in unipolar and bipolar disorder and schizophrenia. We will further delineate the spectrum of efficacy, mechanisms of action and tolerability profile of this and related agents. We also will study risk factors and pathways for the development of depression, to develop public health strategies.Read moreRead less
Deep Brain Stimulation In The Treatment Of Severe Depression
Funder
National Health and Medical Research Council
Funding Amount
$1,008,087.00
Summary
Some patients with depression fail to respond to a variety of standard treatments and in this group, deep brain stimulation (DBS) is being evaluated as an alternative treatment option. This study will investigate the use of DBS applied to a novel brain target site in patients with highly treatment refractory depression.
Rates Of Psychosis Onset In A High Risk Population
Funder
National Health and Medical Research Council
Funding Amount
$310,359.00
Summary
Older studies of people at risk of schizophrenia found that about 35% of them developed psychosis within 1 year. However the risk has decreased lately to as low as 10%. They may still become psychotic but take longer to do so, or they may not develop psychosis at all. We need to study this so that those not “at risk” are not needlessly treated. We will follow up “at risk” people and determine their 6 year outcome. We will do scans to see if there are any brain changes associated with psychosis.
Individualised Vocational Support For Youth With Borderline Personality Disorder: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,359,118.00
Summary
Borderline Personality Disorder (BPD) is a severe mental disorder that can significantly disrupt normal vocational (i.e., education and employment) development. This trial investigates whether early intervention with a specialised Individual Placement and Support (IPS) model for vocational recovery is more effective than usual vocational supports for 15-25 year olds with BPD. It is expected that IPS will result in more days in mainstream employment and education.
Providing Evidence For The Primary Prevention Of The High-prevalence Mental Disorders In Men: The Role Of Diet In The Aetiology Of Depression, Anxiety, And Psychological Distress
Funder
National Health and Medical Research Council
Funding Amount
$300,862.00
Summary
Depression is predicted to become the second-most common cause of disability in the world by 2020, despite the increased energy devoted to recognition and treatment. This study will examine the association between diet quality and depressive and anxiety disorders in men, to identify to what extent diet quality is related to the risk for and/or course of these illnesses.
A Randomised Controlled Trial Of NMDA Antagonist, Memantine, For The Treatment Of Borderline Personality Disorder
Funder
National Health and Medical Research Council
Funding Amount
$993,067.00
Summary
Borderline Personality Disorder (BPD) affects 5.9% of Australians and is a poorly understood mental illness with no clear medication treatment. The key symptoms of BPD all stem from impaired cognitive processes. Our early data shows improvement of symptoms with memantine - a cognitive enhancing drug used in Alzheimer’s disease.We plan to conduct a clinical trial; giving either 20mg memantine or placebo to 150 people with BPD across 2 Victorian sites.